Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
100%(5 trials)

Phase Distribution

Ph phase_1
3
60%
Ph phase_3
2
40%

Phase Distribution

3

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 32 (40.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Pharmacodynamic Evaluation of Intranasal Nalmefene

NCT04828005
completedphase_1

Pharmacokinetic Evaluation of Intranasal Nalmefene

NCT04759768
completedphase_1

Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens

NCT05219669
completedphase_3

A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence

NCT02382276
completedphase_3

A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)

NCT02364947

Clinical Trials (5)

Showing 5 of 5 trials
NCT04828005Phase 1

Pharmacodynamic Evaluation of Intranasal Nalmefene

Completed
NCT04759768Phase 1

Pharmacokinetic Evaluation of Intranasal Nalmefene

Completed
NCT05219669Phase 1

Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens

Completed
NCT02382276Phase 3

A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence

Completed
NCT02364947Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5